Moderna (MRNA)
(Delayed Data from NSDQ)
$84.93 USD
+0.61 (0.72%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$84.93 USD
+0.61 (0.72%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
by Zacks Equity Research
Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.
Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $125.14, moving +0.1% from the previous trading session.
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up
by Zacks Equity Research
Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.
Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug
by Zacks Equity Research
Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
by Zacks Equity Research
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $124.06 in the latest trading session, marking a -0.39% move from the prior day.
Stock Market News for Jan 13, 2021
by Zacks Equity Research
Benchmarks closed in the positive territory on Tuesday as investors remained optimistic on possible fiscal stimulus and vaccine roll out.
Markets Prove Buoyant; KB Home (KNH) Beats Q4 Estimates
by Mark Vickery
KB Home's $1.12 per share was well out in front of the 87 cents in the Zacks consensus, while revenues of $1.19 billion topped the $1.11 billion expected.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
COVID-19 Vaccine Production to Ramp Up
by Zacks Equity Research
COVID-19 Vaccine Production to Ramp Up
Covid-19 Vaccinations Promise to Ramp Up
by Mark Vickery
Guidance for the end of 2020 was to have 20 million Americans with the first half of the two-injection immunization treatment; as of now, only around 9 million Americans have received the first dose.
Moderna (MRNA) Stock Up on Vaccine Pipeline Expansion Plan
by Zacks Equity Research
Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.
4 Reasons for Bank ETFs to Win in 2021
by Sanghamitra Saha
Bank ETFs should stay strong in the coming days on the back of cheaper valuation, Fed's signal for buybacks, Democrat's control over Senate and spike in bond yields.
Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
by Zacks Equity Research
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
Racing Against Time: Covid-19 vs. Vaccines
by Mark Vickery
This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.
What Will Be the Main Economic Drivers in 2021?
by John Blank
With 2020 in the rear-view mirror, we are leaving behind us a plethora of events that affected and shaped our society and economy.
3 Biotech Stocks Worth Adding to Your Portfolio in 2021
by Ekta Bagri
We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $115.09 in the latest trading session, marking a -1.01% move from the prior day.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and AstraZeneca
Company News for Jan 7, 2021
by Zacks Equity Research
Companies in The News Are: CGNG,UNH,MRNA,WBA,ABC,GTH
Moderna (MRNA) COVID-19 Vaccine Gets Authorization in Europe
by Zacks Equity Research
Moderna (MRNA) gets conditional use authorization for coronavirus vaccine, mRNA-1273, for use in adults in EU member states.
Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.
FDA Opposes Dilution of COVID-19 Vaccine Doses: Here's Why
by Indrajit Bandyopadhyay
The FDA is against any changes to the approved dosing regimens for Pfizer (PFE)/BioNTech (BNTX) and Moderna's (MRNA) coronavirus vaccines as demanded by some experts.